Who Owns Glaukos Company?

Glaukos Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Glaukos now?

Glaukos went public on June 25, 2015 (NYSE: GKOS), shifting from venture-backed startup to a widely held medtech company and enabling large institutional and index ownership.

Today ownership is led by U.S. institutional investors and index funds, with founders and executives retaining meaningful stakes while the public float supports liquidity and strategic capital moves. See Glaukos Porter's Five Forces Analysis.

Founders and early ownership of the Glaukos Company trace to a small group of ophthalmic innovators and Southern California medtech backers who organized the venture circa 1998–2001 to commercialize micro‑invasive glaucoma surgery (MIGS) technology.

Founding team

Key founders included Olav B. Bergheim, Richard A. Hill and Mory Gharib, PhD; early technical leadership later included Thomas W. Burns.

Technical origins

The iStent concept arose from collaborations between biomedical engineers and ophthalmic surgeons; inventor credit rests with clinicians and engineers who developed MIGS implants.

Early capital

Seed funding came from angels, friends‑and‑family and specialist ophthalmology venture firms in Southern California prior to institutional Series rounds.

Equity mechanics

Founders and early employees were subject to standard four‑year vesting with one‑year cliffs and founder repurchase rights common to the era.

IP and governance

Early agreements included IP assignment to the company and protective provisions for preferred shareholders introduced in venture rounds.

Pre‑IPO transitions

Founder exits or equity transfers before the IPO were managed through buy‑sell and repurchase provisions to align control with active management and the board.

Public disclosures at IPO and subsequent SEC filings show institutional shareholders and insiders replacing the initial seed investor group over time; for detailed founder and early ownership context see Growth Strategy of Glaukos.

Key points on early ownership

Founders, seed backers and specialized venture firms established initial ownership and governance arrangements that shaped later institutional ownership.

• Founders: Olav B. Bergheim, Richard A. Hill, Mory Gharib, PhD, with technical/CEO leadership from Thomas W. Burns.
• Early funding: angels, friends‑and‑family, ophthalmology‑focused VCs; no public founding cap table percentages disclosed.
• Equity terms: four‑year vesting with one‑year cliffs, founder repurchase rights and IP assignment to the company.
• Transition mechanics: pre‑IPO buy‑sell and repurchase provisions preserved operational control as institutional shareholders increased ownership.

Glaukos SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events shaping who owns Glaukos include venture-stage preferred financing (2007–2014) that diluted founders, a June 25, 2015 IPO at $18 per share raising roughly $100–120 million, broadening to growth and health-care funds, and steady institutional indexation from 2016 through 2025 that left insiders with low- to mid-single-digit ownership.

Current Glaukos ownership is concentrated among U.S. institutional investors (large index families and active healthcare managers), with no controlling shareholder and continued alignment via executive holdings and vested equity.

Major stakeholder profile (2024–2025)

Institutional investors (index funds + active healthcare managers) dominate ownership; insiders retain modest stakes that signal alignment.

• Top 10 institutions typically combine for 45–60% of shares outstanding
• Passive index funds (Vanguard, BlackRock/iShares) are significant holders
• Active managers (Wellington, T. Rowe Price, Fidelity) hold meaningful positions
• Named insiders, including CEO and longtime leader Thomas W. Burns, collectively hold low- to mid-single-digit percentages

For background on strategy implications tied to ownership shifts, see Marketing Strategy of Glaukos

Glaukos PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors of Glaukos comprises a mix of executives and a majority of independent directors with medtech, pharma, and ophthalmology expertise; governance documents and recent proxy disclosures show a standard one-share–one-vote structure and institutional investor oversight.

Proxy statements through 2024–2025 indicate dispersed voting power: no single shareholder consistently exceeds 10–15%, insider ownership remains below control thresholds, and institutional shareholders dominate the register without a controlling investor.

Board governance and voting takeaways

Glaukos governance emphasizes independent oversight, continuity of R&D strategy, and accountability to institutional shareholders.

• Standard one-class capital structure supports equal voting rights for ordinary shareholders
• Majority independent board with specific committee leadership ensures governance checks
• No sustained single-holder control — top holders typically institutional investors each under 15%
• Shareholder proposals focus on ESG and executive compensation rather than control disputes

For context on company purpose and values related to board priorities, see Mission, Vision & Core Values of Glaukos.

Glaukos Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past 3–5 years, Who owns Glaukos has shifted noticeably toward large institutions and passive index funds as market cap growth and broader index inclusion increased institutional holdings and passive ownership concentration.

Market participants and filings indicate management favors public-market financing optionality over dual-class structures or privatization; buybacks would be opportunistic relative to continued R&D and international commercialization investments. See a concise corporate history context at Brief History of Glaukos

Institutional holders rise

Glaukos institutional shareholders now account for a substantial portion of the free float, driven by large asset managers and healthcare-focused funds.

Passive ownership increased

ETF and index fund ownership expanded after index inclusions, reducing liquidity-driven volatility but increasing sensitivity to rebalances.

Event-driven activity

Clinical and regulatory catalysts—especially late-stage retinal readouts—have attracted activist and event-driven investors seeking short-term alpha.

Insider and founder stakes

Founder and executive ownership percentages fell modestly due to dilution from offerings; insider beneficial ownership disclosures through 2025 show executives retain meaningful economic stakes but not control.

Glaukos Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔